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Abstract Recently, the molecular mechanism responsi-
ble for the instability of atherosclerotic plaques has grad-
ually become a hot topic among researchers and clinicians.
Matrix metalloproteinases (MMPs) and vascular endothe-
lial growth factor (VEGF) play an important role in the
processes of formation and development of atherosclerosis.
In this study, we established and employed the transwell
co-culture system of rabbit aortic endothelial cells and
smooth muscle cells to explore the relationship between
fibrin (Fb), fibrinogen (Fg), and/or their degradation
products (FDPs) in relation to the instability of athero-
sclerotic plaques; meanwhile, we observed the effects of
Fg, Fb, and FDPs on the mRNA levels of MMPs and
VEGF as well as on the activation of nuclear factor-kappa
B (NF-jB). We concluded that Fb, Fg, and FDPs are
involved in the progression of the instability of athero-
sclerotic plaques via increasing the expression of MMPs
and VEGF. This effect might be mediated by the NF-rB
pathway.
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Introduction
The instability of atherosclerotic plaques is an important
factor leading to the rupture of plaques and the occurrence
of stroke, and has been drawing increasing attention of
researchers and clinicians. Epidemiological studies have
demonstrated that hyperfibrinogenemia is an independent
risk factor for stroke, as well as that fibrinogen (Fg), fibrin
(Fb), and fibrinogen degradation products (FDPs) are
involved in the formation and development of atheroscle-
rosis (AS) [1, 2]. Fg is a 340 kD glycoprotein which is
constitutively expressed exclusively in hepatocytes [3]. As
a key plasma protein, Fg has a plasma half-life of 3–5 days
and can be converted to Fb in the final step of the coagu-
lation cascade [4]. FDPs are fragments (polypeptides)
produced when either Fg or Fb is broken down by the
enzyme plasmin [5].
Numerous studies have demonstrated that the plasma
levels of Fg, Fb, and FDPs have close association with
vascular diseases. People with high levels of Fg are more
than twice as likely to die of a heart attack or stroke as
people with normal Fg levels [6]. Wada et al. [7] found that
the plasma level of Fb monomer in patients with dissemi-
nated intravascular coagulation (DIC) was significantly
higher than that in patients with pre-DIC or in non-DIC
patients. Gaffney et al. [8] reported that the levels of FDPs
can rise after any thrombotic event, indicating it can be
used to test for DIC. Despite the findings of these studies,
however, the relationship between Fg, Fb, and FDPs and
the instability of atherosclerotic plaques remains unclear.
The aim of the current study was to explore the molecular
mechanisms of Fg, Fb, and FDPs as they are involved in
the instability of atherosclerotic plaques. We established
and employed the transwell co-culture system of rabbit
aortic endothelial cells (ECs) and smooth muscle cells
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(SMCs) to investigate the relationship between Fg, Fb, and/
or their degradation products (FDPs) in relation to the
instability of atherosclerotic plaques.
Materials and methods
Materials
Healthy male rabbits (2 months old, weighing 2–3 kg) were
purchased from the Animal Center of Soochow University
(Suzhou, China). Rabbit SMCs were purchased from the
Institute of Basic Medical Sciences of Chinese Academy of
Medical Sciences, China. Dulbecco’s modified eagle medium
(DMEM) was purchased from Gibco Company, USA. Fetal
bovine serum (FBS) was purchased from Hyclone Company,
USA. Endothelial cell growth supplement (ECGS), Type II
collagenase, and parenzyme were purchased from Sigma
Company, USA. 3-(4,5)-Dimethylthiahiazo(-z-y1)-3,5-di-
phenytetrazoliumromide (MTT) was purchased from Fluka
Company, Sweden. NF-jB inhibitor SN50 was purchased
from UBI Company, USA. RiboPureTM minimal RNA
extraction kit was purchased from Ambion Company, USA.
Agents for reverse transcription and polymerase chain reac-
tion (PCR) were purchased from Shanghai Sangon Biological
Engineering Technology and Service Co. Ltd, China. Mouse
polyclonal antibody to human VIII factor and mouse mono-
clonal anti-rabbit a-SM-actin was purchased from Lab Vision
Company, USA. Relevant secondary antibodies were pur-
chased from Wuhan Boster Biological Engineering Co. Ltd,
China. VEGF, MMP-2, and MMP-8 enzyme-linked immu-
nosorbent assay (ELISA) kits were purchased from BPB
Biology Company, USA. NF-jB active-nucleus transit
detection kit was purchased from Nantong Biyuntian
Biological Technology Co. Ltd, China. Transwell 0.4 and
8 lm-pore size gelatinized polycarbonate membranes were
purchased from Corning Company, USA.
Cell isolation and culture
Primary aortic endothelial cells were isolated from the tho-
racic aortae of healthy male rabbits according to a previously
described method [9]. ECs between the 3rd and 5th passage
and SMCs between the 7th and 10th passage were used for
the experiments. Both ECs and SMCs were cultured in a
humidified 95 % air, 5 % CO2 incubator at 37 C and
maintained in DMEM supplemented with 10 % FBS.
Experimental groups and preparation of Fg, Fb,
and FDPs
The solutions of Fg, Fb, and FDPs at various concentra-
tions were prepared using a previously described method
[10]. The cultured cells were divided into three experi-
mental groups: Fg, Fb, and FDPs intervention groups. Each
group was subdivided into 6 subgroups (0, 0.5, 1.5, 3.0,
4.5, and 6.0 mg/ml) according to the concentrations of Fg,
Fb, and FDPs. SN50 (50 lg/ml) was administered to the
groups, in which NF-jB was activated, 1 h before adding
Fg, Fb, and FDPs.
Establishment of the rabbit aorta ECs–SMCs
co-culture system
Rabbit aorta ECs–SMCs co-culture system was established
according to our previous study [11]. ECs (10 9 104 cells/
ml) in logarithmic periods were seeded onto Transwell
inserts, and then put into 12-well plates; SMCs
(10 9 104 cells/ml) were cultured into the bottom chamber
of 12-well plates and then cultured to confluence. After
being cultured in serum-free DMEM for 24 h, the Trans-
well membranes cultured with confluent ECs were inserted
into plates cultured with SMCs, thus, the ECs–SMCs co-
culture system was established. ECs were seeded into the
inner chamber with 300 ll DMEM, and SMCs in the outer
chamber with 1200 ll, they were then incubated with Fg,
Fb, or FDPs (outer chamber) for 24 h. SN50 was intro-
duced into the chambers 1 h before adding Fg, Fb, or
FDPs. After treatment, the supernatant was gathered and
stored at -70 C. Total mRNA was extracted from the
co-cultured cells according to the one-step method (Trizol
agent).
NF-jB activation
Inactive NF-jB is a cytoplasmic complex that binds with
jB inhibitor (IjB)-a. Once activated, IjB-a is phosphated
and degradated by the ubiquitin–proteasome pathway. The
separation of IjB-a from NF-jB exposes the sequence
binding the nucleus, which leads to the translocation of
NF-jB into the nucleus and the transcription of NF-jB-
dependent genes. The activation of NF-jB is detected by
the ability of its main subunit, p65, to translocate from
cytoplasm into nuclei using immunofluorescence staining.
Here, NF-jB p65 is stained with red fluorescence and the
nucleus was stained with blue.
To establish the ECs–SMCs indirect co-culture system,
SMCs were seeded onto the coverslips (18 mm 9 18 mm)
in the bottom of 6-well plates, and ECs were seeded onto
0.4 mm pore size Transwell inserts. The confluent cells
were cultured with serum-free DMEM for 24 h, then
treated with Fg, Fb, or FDPs (0.5, 3.0, or 6.0 mg/ml) for
24 h. After treatment, the cells were fixed with 4 % para-
formaldehyde, packed in silver papers, and stored at
-20 C for staining.
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Cells were rinsed in 0.1 M phosphate buffered saline
(PBS) at room temperature (RT) and then incubated in
blocking buffer for 1 h. Subsequently, the section was
incubated with anti-NF-jB-p65 antibody at 4 C overnight,
followed by anti-rabbit Cy3 at RT for 1 h. Later, the sec-
tion was incubated with 2-(4-Amidinophenyl)-6-indole-
carbamidine dihydrochloride (DAPI) at RT for 5 min
before mounting. NF-jB was stained red and the nucleus
was stained with DAPI blue. The merger of red and blue
suggests that NF-jB p65 has transferred into the nucleus
and has been activated.
Examination of MMP-2 mRNA and VEGF mRNA
Total RNA was extracted from co-cultured cells strictly fol-
lowing the procedures outlined in the manual included in the
kit. Reverse transcription was carried out in a 20 ll reactive
system. PCR was performed with Taq DNA polymerase
(30 cycles, 94 C for 30 s, 55.5 C for 30 s, and 72 C for
30 s), followed by a final extension at 72 C for 7 min in a 50 ll
reactive system. Rabbit MMP-2 upstream primer: 50-AGCCT
TCTCACCCCCACCTG-30, downstream primer: 50-GCCCTT
ATCCCACTGCCCC-30 [12]; Rabbit VEGF upstream primer:
50-GACATCTTCCAGGAGTACCC-30, downstream pri-
mer: 50-TGAGGTTTGATCCGCATGAT-30 [13]; GAPDH
upstream primer: 50-ACGAATTTGGCTACAGCAACAG
G-30, downstream primer: 50-GGTCTGGGATGGAAACTG
TGAAG-30 [14]. The amplified fragments had an expected
length of 313 bp, 157 bp, and 196 bp, respectively. The PCR
reaction products (6 ll) were subjected to 1.5 % agarose gel
electrophoresis and stained with ethidium bromide. The
intensity of the specific bands was quantified by image
analysis.
Detection of contents of MMP-2, MMP-8, and
VEGF in medium
The MMP-2, -8, and VEGF content in the medium were
detected by cellular ELISA kits using a DG3022A-type
cellular enzyme-linked immunosorbent detection apparatus
at 450 nm. The standard curve was made according to the
absorbance of standard samples, and the MMP-2, -8, and
VEGF content was calculated using the standard curve.
MMP-2 and VEGF activation assay
Levels and degrees of activation of MMP-2 were examined
in co-cultured cells by use of the gelatin zymography
method [15] on sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) containing gelatin.
Supernatant aliquots containing 150 lg of total protein
were used. The mixture (25 ll) of supernatant aliquots and
buffer solutions (1:1) was loaded onto a polyacrylamide gel
(5 % stacking gel, 10 % separating gel containing 0.5 %
gelatin). After electrophoresis, the gels were washed with
2.5 % TritonX-100 solution twice, 45 min each time,
and then incubated with medium (containing 50 mmol/L
Tris–HCl, 50 mmol/L NaCl, 10 mmol/L CaCl2, 1 lmol/L
ZnCl2, 1 % TritonX-100, pH 7.6) at 37 C for 48 h. The
gels were stained with 0.05 % Coomassie Blue R-250 for
3 h before being decolored. MMP-2 band intensity was
quantified by the Quantity One Image analysis system, and
the data were expressed as the bands’ digestibility: bands
digestibility = area of bands 9 (gray value of bands–gray
value of background).
The activity of VEGF was determined by use of MTT
methods [16]. ECs (1 9 105 cells/ml) from the 3rd to 5th
passages were pre-incubated with the gathered medium and
standard VEGF for 48 h. Subsequently, MTT was added
into the medium at a final concentration of 0.5 mg/ml, and
the cells were incubated for another 4 h in a CO2 incubator
at 37 C. Resultant insoluble formazan crystal was dis-
solved in dimethyl sulfoxide (DMSO) at 37 C for 30 min.
With blank control at the zero-setting, the absorbance was
detected at 570 nm (OD570). The activity of VEGF was
expressed as OD570 value of samples/OD570 value of
standards.
Statistical analysis
For all quantitative experiments, statistical analyses of data
were performed using either an unpaired t test or a one-way
analysis of variance (ANOVA) by SPSS11.5 software.
Values are cited as mean ± standard deviation (SD).
P \ 0.05 is considered a statistically significant probability.
Results
NF-jB activation
Fb and FDPs (3.0–6 mg/ml) activated NF-jB of ECs and
SMCs. However, the activated NF-jB was not found in the
Fg groups, as well as the Fb and FDPs groups whose
concentrations were lower than 0.5 mg/ml. (Fig. 1).
mRNA levels of MMP-2 and VEGF
The mRNA level of MMP-2 was upregulated with an increase
on culture concentrations when exposed to Fg (4.5–6.0 mg/
ml), Fb (3.0–6.0 mg/ml), and FDPs (0.5–6.0 mg/ml). VEGF
mRNA level had a similar effect under treatments of Fg, Fb
(1.5–6.0 mg/ml), and FDPs (0.5–6.0 mg/ml). NF-jB inhibi-
tor SN50 treatment prevented the upregulation of their mRNA
levels (Fig. 2).
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MMP-2, MMP-8, and VEGF contents
MMP-2, MMP-8, and VEGF contents were nearly increased
as a result of an increase in culture concentrations in the
(4.5–6.0), (3.0–4.5), and (1.5–6.0) mg/ml Fg groups; only
MMP-8 was slightly decreased in the 6.0 mg/ml Fg group;
MMP-2 content increased significantly in the 3.0–6.0 mg/ml
Fb groups, as well as MMP-8 and VEGF contents in the
Fig. 1 The effect of Fg, Fb, and FDPs on the activation of NF-jB in
ECs and SMCs. ECs between the 3rd and 5th passage and SMCs
between the 7th and 10th passage were used for the experiments. Both
ECs and SMCs were cultured in DMEM containing 10 % FBS. Red
fluorescence indicates NF-jB p65 staining and blue indicates DAPI
staining. a 3.0 and 6.0 mg/ml, but not 0.5 mg/ml of Fb initiated the
activation of NF-jB in ECs; b 3.0 and 6.0 mg/ml, but not 0.5 mg/ml
of Fb initiated the activation of NF-jB in SMCs; c 3.0 and 6.0 mg/ml,
but not 0.5 mg/ml of FDPs initiated the activation of NF-jB in ECs;
d 3.0 and 6.0 mg/ml, but not 0.5 mg/ml of FDPs initiated the
activation of NF-jB in SMCs. Bar = 150 lm
32 Mol Cell Biochem (2013) 383:29–37
123
1.5–6.0 mg/ml Fb groups; FDPs resulted in a markedly
increased content of MMP-2, -8, and VEGF that began at
1.5 mg/ml and reached its peak at 4.5 mg/ml, and then
declined after 6.0 mg/ml. SN50 decreased the contents of
MMP-2 and VEGF in the Fb and FDPs (4.5–6.0 mg/ml)
groups, but no changes in MMP-8 levels were detected in
SN50-treated groups (Fig. 3).
Activity of MMP-2 and VEGF
Fb (4.5–6.0 mg/ml) and FDPs (1.5–6.0 mg/ml) enhanced
the activity of MMP-2 and VEGF. The activity of MMP-2
increased with 4.5–6.0 mg/ml Fg and VEGF increased with
1.5–6.0 mg/ml. SN50 inhibited the effect of Fb and FDPs
(3.0–6.0 mg/ml) (Figs. 4, 5).
Fig. 2 The effects of Fg, Fb, and FDPs on the mRNA levels of
MMP-2 and VEGF in co-cultured ECs–SMCs. The establishment of
ECs–SMCs co-culture system was described in the ‘‘Materials and
methods’’ section. a Fg could significantly increase the mRNA levels
of MMP-2 and VEGF in co-cultured ECs–SMCs. b Fb could
significantly increase the mRNA levels of MMP-2 and VEGF in co-
cultured ECs–SMCs, and the treatment of 50 lg/ml SN50, NF-jB
inhibitor, showed inhibitory effect against this increase. c FDPs could
significantly increase the mRNA levels of MMP-2 and VEGF in co-
cultured ECs–SMCs, and the treatment of 50 lg/ml SN50, NF-jB
inhibitor, showed inhibitory effect against this increase. Data are
shown as mean ± SD for six replicates (n = 6), which are a
representative of three independent experiments. #P \ 0.05 and
##P \ 0.01, compared with the groups without Fg, Fb, or FDPs
treatment; *P \ 0.05 and **P \ 0.01, compared with the groups
without SN50 treatment
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Discussion
At present, the molecular mechanisms responsible for the
instability of atherosclerotic plaques have become a hot
topic among clinicians and researchers. Instability of ath-
erosclerotic plaques implies two meanings: (a) the shaded
plaques are prone to cause congestion in small vascular
compartments; (b) the instability of plaques is apt to form
thrombosis, which results in further occlusion of vessels.
The degradation of fibrous caps by MMPs and neovascu-
larization in plaques are major events involving in the
instability of atherosclerotic plaques. Multiple studies have
demonstrated that MMP-2, MMP-8, and VEGF play an
important role in the instability of atherosclerotic plaques
[17, 18].
Fibrinogen is one of the independent reconcilable fac-
tors leading to stroke. An increase in plasma Fg and its
degradation products, Fb and FDPs, can stimulate the
proliferation and transformation of SMCs, leading to the
sclerosis of vessel walls and the narrowing of vessels.
Elevated Fg, Fb, and FDPs in fibrous caps also contribute
to the rupture of atherosclerotic plaques by enhancing
endothelial permeability and migration of SMCs [2]. Along
these lines, we find that the instability of plaques is related
to the mRNA levels and contents of MMPs and VEGF
associated with the degradation of matrices and neovas-
cularization. Thus, we hypothesize that the injury of ECs
and the proliferation and migration of SMCs are accom-
panied by the degradation of matrices and neovasculari-
zation [19].
Matrix metalloproteinases-2 (MMP-2) is recognized as an
important degradation enzyme of type IV glutin protein.
Moreover, active MMP-2 contributes to the neovasculari-
zation through its degradation of matrices [20]. In the pro-
gression of AS, MMP-2 is involved in the migration of
vascular SMCs from the media to the intima through the
basement membrane, which mainly consists of type IV glutin
protein. Recent studies demonstrate that there is increased
expression and activity of MMP-2 in human instable ath-
erosclerotic plaques [21]. Therefore, MMP-2 plays an
Fig. 3 MMP-2, MMP-8, and VEGF contents in the supernatant of
medium in which ECs–SMCs were co-cultured. The contents were
assayed by ELISA kit. The establishment of ECs–SMCs co-culture
system was described in the ‘‘Materials and methods’’ section.
a Treatment with Fg, Fb, and FDPs at various concentrations could
induce a significant increase in the content of MMP-2 in the
supernatant of medium, and the treatment of 50 lg/ml SN50, NF-jB
inhibitor, showed inhibitory effect against this increase induced by Fb
and FDPs. b Treatment with Fg, Fb, and FDPs at various concen-
trations could induce a significant increase in the content of MMP-8
in the supernatant of medium, but the treatment of 50 lg/ml SN50,
NF-jB inhibitor, did not have inhibitory effect against this increase
induced by Fb and FDPs. c Treatment with Fg, Fb, and FDPs at
various concentrations could induce a significant increase in the
content of VEGF in the supernatant of medium, and the treatment of
50 lg/ml SN50, NF-jB inhibitor, showed inhibitory effect against
this increase induced by Fb and FDPs. Data are shown as mean ± SD
for five replicates (n = 5), which are a representative of three
independent experiments. #P \ 0.05 and ##P \ 0.01, compared with
the groups without Fg, Fb, or FDPs treatment; *P \ 0.05 and
**P \ 0.01, compared with the groups without SN50 treatment
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important role in the instability of atherosclerotic plaques
through regulating the degradation of plaque matrices and
neovascularization. In our study, we used the vascular ECs–
SMCs co-culture system and found that high levels
(4.5–6.0 mg/ml) of Fg dramatically increased the mRNA
level, content, and activity of MMP-2. Consistent with this
finding, Fb (3.0–6.0 mg/ml) obviously enhanced the mRNA
level, content, and activity of MMP-2. As far as FDPs
(0.5–6.0 mg/ml) were concerned, the mRNA level of MMP-
2 was upregulated in a concentration-dependent manner.
However, the increase in content and activity of MMP-2 was
found only in the 1.5–6.0 mg/ml FDPs groups, suggesting
there may exist post-transcriptional regulatory factors that
can regulate the mRNA-protein-activity chain of MMP-2.
Matrix metalloproteinases-8 (MMP-8) is recognized as a
degradated enzyme and mainly degradates type I–VI glutin
protein, elastin, fibronectin, and laminin. Its ability to de-
gradate glutin protein is twice that of other interstitial
collagenases [22]. Growing evidence indicates that MMP-8
is expressed in the ECs and SMCs of human atherosclerotic
plaques, cooperates with macrophage cells leading to the
degradation of type I glutin, and coexists with their deg-
radation fragments in the ‘‘shoulder’’ of plaques. These
results suggest that MMP-8 plays an important role in the
instability of atherosclerotic plaques [23–25]. Furthermore,
MMP-8 not only prompts the degradation of matrix via
activating MMP-2, -3, and -9 [26], but also regulates the
expression of cytokine factors IL-1b, IL-8, TNF-a, and T
cell membrane proteins CD2, 4, and 8, thereby aggravating
the inflammatory response [27]. In our present work,
we showed that the level of MMP-8 increased in a
concentration-dependent manner when exposed to Fg
(3.0–6.0 mg/ml) Fb, and FDPs (1.5–6.0 mg/ml), and
reached a peak at 4.5 mg/ml. However, the mRNA level
and activity of MMP-8 were not examined because of the
absence of its rabbit primer and activity detection method.
Fig. 4 Activity of MMP-2 and VEGF in the supernatant of medium
in which ECs–SMCs were co-cultured. The activity was assayed by
gelatin zymography method. Supernatant aliquots containing 150 lg
of total protein were used. The establishment of ECs–SMCs co-
culture system was described in the ‘‘Materials and methods’’ section.
a Fg enhanced the activity of MMP-2 in the supernatant. b Fb
enhanced the activity of MMP-2 in the supernatant, and the treatment
of 50 lg/ml SN50, NF-jB inhibitor, showed inhibitory effect against
this enhancement. c FDPs enhanced the activity of MMP-2 in the
supernatant, and the treatment of 50 lg/ml SN50, NF-jB inhibitor,
showed inhibitory effect against this enhancement. Data are presented
as mean ± SD for four replicates (n = 4), which are a representative
of three independent experiments. Bands digestibility = area of
bands 9 (gray value of bands–gray value of background). #P \ 0.05
and ##P \ 0.01, compared with the groups without Fg, Fb, or FDPs
treatment; *P \ 0.05 and **P \ 0.01, compared with the groups
without SN50 treatment
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Neovascularization has been recognized as a cardinal
feature of unstable plaques. So far, VEGF is the only growth
factor tested that has a specific role in cellular karyokinesis,
and its effect in the neovascularization has been attentioned
by increasingly more scholars. The effects of VEGF in
neovascularization may be due to its ability to promote the
expression of MMPs (mainly MMP-2), degradate the basic
vascular membrane, and enhance the migration of ECs [28].
In the early stages, VEGF can improve the impairment of
vascular intima by stimulating neovascular formation in
atherosclerotic plaques [29]. However, with the increasing
neovascular ingrowth in plaques, all kinds of inflammation
factors and lipoprotein deposits are aggregated, which fur-
ther lead to the degradation of matrices, thinning of fibrous
caps, and cause plaques to become brittle and rupture.
Therefore, the role played by VEGF in clinical diseases is
due to the balance it exerts on improvement and proliferation
of VECs, which is the balance between atherosclerotic pla-
ques’ progress and neovascular formation. Consistent with
this, we found that Fg ([1.5 mg/ml), Fb, and FDPs all
enhanced the mRNA level and content of VEGF as well as its
subsequent activity.
Inflammation plays a central role in the progress of AS.
NF-jB induces the expression of many inflammatory
mediators as a necessary transcription factor [30]. Related
expression productions induced by NF-jB contribute to the
formation and development of AS at the site of inflammation
by aggregating vascular inflammation and causing it to lin-
ger. The inflammation pathway induced by NF-jB family is
a common method by which many risk factors promote the
development of AS [31]. In our study, we found that only Fb
(3.0–6.0 mg/ml) and FDPs (3.0–6.0 mg/ml) resulted in the
enhanced activation of NF-jB of ECs and SMCs, but Fg and
lower levels of Fb and FDPs did not. We next explored the
relationship between the activation of NF-jB and the mRNA
levels and contents of MMP-2, -8, and VEGF using the NF-
jB inhibitor SN50 and found that SN50 could decrease the
mRNA levels and contents of MMP-2 and VEGF, but not
MMP-8. Therefore, we concluded that Fb and FDPs regulate
the expression of MMP-2 and VEGF via an NF-jB-depen-
dent pathway.
However, we are pressed to ask why SN50 does not affect
the mRNA level and content of MMP-8, and why Fb and
FDPs could activate the NF-jB pathway in ECs and SMCs,
but not Fg? There are two small peptides, Aa1–16 and Bb1–14,
which have been designated fibrinopeptides A and B (FPA,
FPB) in the N-terminal regions of FgAa and Bb chains. The
interaction of thrombin with Fb causes the release of the two
small peptides, which results in the formation of Fb. Aa1–16
and Bb1–14 are the only differences between Fg and Fb [32].
However, neither the cleavage of these peptides that changes
the crystal structure of Fg or Fb, nor the one which activates
the NF-jB pathway are not clear. More recently, mitogen-
activated protein (MAP) kinases and NF-jB have been
identified as important molecules that regulate the trans-
duction of the Fgc117–133/ICAM-1 signal pathway. Previous
studies also report that protein kinase C (PKC), the upstream
of MAPK, is involved in the regulation of the VE-cadherin/
FbBb15–42 signal pathway [33]. These results suggest that
Fg, Fb, and FDPs may regulate the mRNA levels, contents,
and subsequent activities of MMP-2 and VEGF through the
PKC and MAPK-mediated activation of NF-rB.
In this study, we show that Fg, Fb, and FDPs are involved
in the progress of the instability of atherosclerotic plaques by
increasing the mRNA levels, contents, and activities of
MMP-2, -8, and VEGF. This effect may be mediated by the
NF-rB pathway. Regulation of the expression of these pro-
teins and the NF-rB pathway may have a favorable effect on
the treatment and prognosis of AS.
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